Moolec Science (MLECW) Cash from Operations (2022 - 2024)
Moolec Science (MLECW) posted Cash from Operations of 2153878.0 for Q4 2024, down 91.26% sequentially from 1126149.0 in Q3 2024, and up 44.83% YoY from 1487144.58 in Q1 2024.
Moolec Science (MLECW) Cash from Operations (2022 - 2024) Analysis & Trends
Moolec Science has reported Cash from Operations for 3 years, with the latest figure at 2153878.0 in Q4 2024.
- Quarterly Cash from Operations rose 44.83% year-over-year to 2153878.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 41925394.0 (up 188.47% YoY) and the FY2025 annual result came in at 3636413.0, down 90.81% from the prior year.
- Cash from Operations declined to 2153878.0 in Q4 2024 per MLECW's latest filing, from 1126149.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 47845572.0 in Q2 2024 and troughed at 36312138.0 in Q2 2023.
- A 3-year average of 494126.33 and a median of 1434856.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 18171.76% in 2023, then soared 231.76% in 2024.
- Over 3 years, Cash from Operations stood at 573367.0 in 2022, then slumped by 780.94% to 3904296.0 in 2023, then surged by 44.83% to 2153878.0 in 2024.
- According to Business Quant data, Cash from Operations over the past three periods registered 2153878.0, 1126149.0, and 47845572.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.15 Mn |
| Dec 31, 2024 | -2.15 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | 47.85 Mn |
| Jun 30, 2024 | 47.85 Mn |
| Mar 31, 2024 | -2.64 Mn |
| Mar 31, 2024 | -2.64 Mn |
| Dec 31, 2023 | -3.90 Mn |
| Dec 31, 2023 | -3.90 Mn |
| Sep 30, 2023 | -1.74 Mn |
| Sep 30, 2023 | -1.74 Mn |
| Jun 30, 2023 | -36.31 Mn |
| Jun 30, 2023 | -36.31 Mn |
| Mar 31, 2023 | -5.43 Mn |
| Mar 31, 2023 | -5.43 Mn |
| Dec 31, 2022 | 573,367.00 |
| Dec 31, 2022 | 573,367.00 |
| Sep 30, 2022 | 9,648.00 |
| Sep 30, 2022 | 9,648.00 |